Lung Cancer | Edward Garon, MD, MS

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 3: Second- and later-line treatment for patients with metastatic NSCLC without a targetable tumor mutation who have experienced disease progression on a checkpoint inhibitor alone or combined with chemotherapy — Dr Garon. CME information and select publications